{"pmid":32327413,"title":"Genetic Roadmap for Kidney Involvement of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.","text":["Genetic Roadmap for Kidney Involvement of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.","Clin J Am Soc Nephrol","Zhang, Yue-Miao","Zhang, Hong","32327413"],"journal":"Clin J Am Soc Nephrol","authors":["Zhang, Yue-Miao","Zhang, Hong"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327413","week":"202017|Apr 20 - Apr 26","doi":"10.2215/CJN.04370420","keywords":["covid-19","kidney involvement; severe acute respiratory syndrome coronavirus 2; humen ace2; genetic perspective"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664996914843615233,"score":8.518259,"similar":[{"pmid":32314810,"title":"Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2).","text":["Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2).","Neurologic sequelae can be devastating complications of respiratory viral infections. We report the presence of virus in neural and capillary endothelial cells in frontal lobe tissue obtained at postmortem examination from a patient infected with Severe Acute Respiratory Syndrome Coronavirus-2. Our observations of virus in neural tissue, in conjunction with clinical correlates of worsening neurologic symptoms, pave the way to a closer understanding of the pathogenic mechanisms underlying CNS involvement. This article is protected by copyright. All rights reserved.","J Med Virol","Paniz-Mondolfi, Alberto","Bryce, Clare","Grimes, Zachary","Gordon, Ronald E","Reidy, Jason","Lednicky, John","Sordillo, Emilia Mia","Fowkes, Mary","32314810"],"abstract":["Neurologic sequelae can be devastating complications of respiratory viral infections. We report the presence of virus in neural and capillary endothelial cells in frontal lobe tissue obtained at postmortem examination from a patient infected with Severe Acute Respiratory Syndrome Coronavirus-2. Our observations of virus in neural tissue, in conjunction with clinical correlates of worsening neurologic symptoms, pave the way to a closer understanding of the pathogenic mechanisms underlying CNS involvement. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Paniz-Mondolfi, Alberto","Bryce, Clare","Grimes, Zachary","Gordon, Ronald E","Reidy, Jason","Lednicky, John","Sordillo, Emilia Mia","Fowkes, Mary"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314810","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25915","keywords":["cns infection","sars-cov-2","endothelium","neuroinvasion","neurotropism"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664714520176623616,"score":45.64479},{"pmid":32273593,"title":"Kidney involvement in COVID-19 and rationale for extracorporeal therapies.","text":["Kidney involvement in COVID-19 and rationale for extracorporeal therapies.","Nat Rev Nephrol","Ronco, Claudio","Reis, Thiago","32273593"],"journal":"Nat Rev Nephrol","authors":["Ronco, Claudio","Reis, Thiago"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32273593","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41581-020-0284-7","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664637190216351745,"score":44.661777},{"pmid":32335367,"title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.","text":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.","BACKGROUND AND AIM: As a result of its rapid spread in various countries around the world, on March 11, 2020, WHO issued an announcement of the change in coronavirus disease 2019 status from epidemic to pandemic disease. The virus that causes this disease is indicated originating from animals traded in a live animal market in Wuhan, China. Severe Acute Respiratory Syndrome Coronavirus 2 can attack lung cells because there are many conserved receptor entries, namely Angiotensin Converting Enzyme-2. The presence of this virus in host cells will initiate various protective responses leading to pneumonia and Acute Respiratory Distress Syndrome. This review aimed to provide an overview related to this virus and examine the body's responses and possible therapies. METHOD: We searched PubMed databases for Severe Acute Respiratory Syndrome Coronavirus-2, Middle East respiratory syndrome-related coronavirus and Severe Acute Respiratory Syndrome Coronavirus. Full texts were retrieved, analyzed and developed into an easy-to-understand review. RESULTS: We provide a complete review related to structure, origin, and how the body responds to this virus infection and explain the possibility of an immune system over-reaction or cytokine storm. We also include an explanation of how this virus creates modes of avoidance to evade immune system attacks. We further explain the therapeutic approaches that can be taken in the treatment and prevention of this viral infection. CONCLUSION: In summary, based on the structural and immune-evasion system of coronavirus, we suggest several approaches to treat the disease.","Diabetes Metab Syndr","Astuti, Indwiani","Ysrafil","32335367"],"abstract":["BACKGROUND AND AIM: As a result of its rapid spread in various countries around the world, on March 11, 2020, WHO issued an announcement of the change in coronavirus disease 2019 status from epidemic to pandemic disease. The virus that causes this disease is indicated originating from animals traded in a live animal market in Wuhan, China. Severe Acute Respiratory Syndrome Coronavirus 2 can attack lung cells because there are many conserved receptor entries, namely Angiotensin Converting Enzyme-2. The presence of this virus in host cells will initiate various protective responses leading to pneumonia and Acute Respiratory Distress Syndrome. This review aimed to provide an overview related to this virus and examine the body's responses and possible therapies. METHOD: We searched PubMed databases for Severe Acute Respiratory Syndrome Coronavirus-2, Middle East respiratory syndrome-related coronavirus and Severe Acute Respiratory Syndrome Coronavirus. Full texts were retrieved, analyzed and developed into an easy-to-understand review. RESULTS: We provide a complete review related to structure, origin, and how the body responds to this virus infection and explain the possibility of an immune system over-reaction or cytokine storm. We also include an explanation of how this virus creates modes of avoidance to evade immune system attacks. We further explain the therapeutic approaches that can be taken in the treatment and prevention of this viral infection. CONCLUSION: In summary, based on the structural and immune-evasion system of coronavirus, we suggest several approaches to treat the disease."],"journal":"Diabetes Metab Syndr","authors":["Astuti, Indwiani","Ysrafil"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335367","week":"202018|Apr 27 - May 03","doi":"10.1016/j.dsx.2020.04.020","keywords":["ace2","covid-19","pandemic","sars-cov-2","wuhan"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1665172301998456833,"score":41.462833},{"pmid":32173241,"pmcid":"PMC7128959","title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","text":["Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2.","J Microbiol Immunol Infect","Lai, Chih-Cheng","Liu, Yen Hung","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Yen, Muh-Yen","Ko, Wen-Chien","Hsueh, Po-Ren","32173241"],"abstract":["Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2."],"journal":"J Microbiol Immunol Infect","authors":["Lai, Chih-Cheng","Liu, Yen Hung","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Yen, Muh-Yen","Ko, Wen-Chien","Hsueh, Po-Ren"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173241","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.jmii.2020.02.012","keywords":["2019-ncov","acute respiratory disease","asymptomatic carrier","covid-19","coronavirus","sars-cov-2","wuhan pneumonia"],"source":"PubMed","topics":["Mechanism","Treatment","Prevention"],"weight":1,"locations":["Wuhan","China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Chloroquine","remdesivir"],"_version_":1664640874662854656,"score":41.44643},{"pmid":32171867,"pmcid":"PMC7102560","title":"Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.","text":["Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.","OBJECTIVES: Previous studies on the pneumonia outbreak caused by the 2019 novel coronavirus disease (COVID-19) were based on information from the general population. However, limited data was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reactivation. This study aimed to evaluate the clinical characteristics of the SARS-CoV-2 reactivation. METHODS: Clinical records, laboratory results, and chest CT scans were retrospectively reviewed for 55 patients with laboratory-confirmed COVID-19 pneumonia (i.e., with throat swab samples that were positive for SARS-CoV-2) who were admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from Jan. 8 to Feb. 10, 2020. RESULTS: All 55 patients had a history of epidemiological exposure to COVID-19, and 5 (9%) patients who discharged from hospital presented with SARS-CoV-2 reactivation. Among the 5 reactivated patients, other symptoms were also observed, including fever, cough, sore throat, and fatigue. One of the 5 patients had progressive lymphopenia (from 1.3 to 0.56x10(9) cells per L) and progressive neutrophilia (from 4.5 to 18.28x10(9) cells per L). All 5 reactivated patients presented normal aminotransferase levels. Throat swab samples from the 5 reactivated patients were tested for SARS-CoV-2, indicating all positive for the virus. CONCLUSIONS: Findings from this small group of cases suggested that there was currently evidence for reactivation of SARS-CoV-2 and there might be no specific clinical characteristics to distinguish them.","J Infect","Ye, Guangming","Pan, Zhenyu","Pan, Yunbao","Deng, Qiaoling","Chen, Liangjun","Li, Jin","Li, Yirong","Wang, Xinghuan","32171867"],"abstract":["OBJECTIVES: Previous studies on the pneumonia outbreak caused by the 2019 novel coronavirus disease (COVID-19) were based on information from the general population. However, limited data was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reactivation. This study aimed to evaluate the clinical characteristics of the SARS-CoV-2 reactivation. METHODS: Clinical records, laboratory results, and chest CT scans were retrospectively reviewed for 55 patients with laboratory-confirmed COVID-19 pneumonia (i.e., with throat swab samples that were positive for SARS-CoV-2) who were admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from Jan. 8 to Feb. 10, 2020. RESULTS: All 55 patients had a history of epidemiological exposure to COVID-19, and 5 (9%) patients who discharged from hospital presented with SARS-CoV-2 reactivation. Among the 5 reactivated patients, other symptoms were also observed, including fever, cough, sore throat, and fatigue. One of the 5 patients had progressive lymphopenia (from 1.3 to 0.56x10(9) cells per L) and progressive neutrophilia (from 4.5 to 18.28x10(9) cells per L). All 5 reactivated patients presented normal aminotransferase levels. Throat swab samples from the 5 reactivated patients were tested for SARS-CoV-2, indicating all positive for the virus. CONCLUSIONS: Findings from this small group of cases suggested that there was currently evidence for reactivation of SARS-CoV-2 and there might be no specific clinical characteristics to distinguish them."],"journal":"J Infect","authors":["Ye, Guangming","Pan, Zhenyu","Pan, Yunbao","Deng, Qiaoling","Chen, Liangjun","Li, Jin","Li, Yirong","Wang, Xinghuan"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32171867","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.jinf.2020.03.001","keywords":["covid-19","ct scan","laboratory medicine","sars-cov-2"],"source":"PubMed","topics":["Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874683826176,"score":41.44349}]}